Identification of FDA-approved antivirulence drugs targeting the Pseudomonas aeruginosa quorum sensing effector protein PqsE

The ability of the bacterial pathogen Pseudomonas aeruginosa to cause both chronic and acute infections mainly relies on its capacity to finely modulate the expression of virulence factors through a complex network of regulatory circuits, including the pqs quorum sensing (QS) system. While in most Q...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Valerio Baldelli, Francesca D’Angelo, Viola Pavoncello, Ersilia Vita Fiscarelli, Paolo Visca, Giordano Rampioni, Livia Leoni
Formato: article
Lenguaje:EN
Publicado: Taylor & Francis Group 2020
Materias:
Acceso en línea:https://doaj.org/article/7e2d2cbeaef94dbdacc17226a46ffa91
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:7e2d2cbeaef94dbdacc17226a46ffa91
record_format dspace
spelling oai:doaj.org-article:7e2d2cbeaef94dbdacc17226a46ffa912021-11-17T14:21:58ZIdentification of FDA-approved antivirulence drugs targeting the Pseudomonas aeruginosa quorum sensing effector protein PqsE2150-55942150-560810.1080/21505594.2020.1770508https://doaj.org/article/7e2d2cbeaef94dbdacc17226a46ffa912020-12-01T00:00:00Zhttp://dx.doi.org/10.1080/21505594.2020.1770508https://doaj.org/toc/2150-5594https://doaj.org/toc/2150-5608The ability of the bacterial pathogen Pseudomonas aeruginosa to cause both chronic and acute infections mainly relies on its capacity to finely modulate the expression of virulence factors through a complex network of regulatory circuits, including the pqs quorum sensing (QS) system. While in most QS systems the signal molecule/receptor complexes act as global regulators that modulate the expression of QS-controlled genes, the main effector protein of the pqs system is PqsE. This protein is involved in the synthesis of the QS signal molecules 2-alkyl-4(1H)-quinolones (AQs), but it also modulates the expression of genes involved in virulence factors production and biofilm formation via AQ-independent pathway(s). P. aeruginosa pqsE mutants disclose attenuated virulence in plant and animal infection models, hence PqsE is considered a good target for the development of antivirulence drugs against P. aeruginosa. In this study, the negative regulation exerted by PqsE on its own transcription has been exploited to develop a screening system for the identification of PqsE inhibitors in a library of FDA-approved drugs. This led to the identification of nitrofurazone and erythromycin estolate, two antibiotic compounds that reduce the expression of PqsE-dependent virulence traits and biofilm formation in the model strain P. aeruginosa PAO1 at concentrations far below those affecting the bacterial growth rate. Notably, both drugs reduce the production of the PqsE-controlled virulence factor pyocyanin also in P. aeruginosa strains isolated from cystic fibrosis patients, and do not antagonize the activity of antibiotics commonly used to treat P. aeruginosa infection.Valerio BaldelliFrancesca D’AngeloViola PavoncelloErsilia Vita FiscarelliPaolo ViscaGiordano RampioniLivia LeoniTaylor & Francis Grouparticlepseudomonas aeruginosaantivirulence strategyquorum sensing inhibitionnitrofurazoneerythromycin estolatescreeningpqseInfectious and parasitic diseasesRC109-216ENVirulence, Vol 11, Iss 1, Pp 652-668 (2020)
institution DOAJ
collection DOAJ
language EN
topic pseudomonas aeruginosa
antivirulence strategy
quorum sensing inhibition
nitrofurazone
erythromycin estolate
screening
pqse
Infectious and parasitic diseases
RC109-216
spellingShingle pseudomonas aeruginosa
antivirulence strategy
quorum sensing inhibition
nitrofurazone
erythromycin estolate
screening
pqse
Infectious and parasitic diseases
RC109-216
Valerio Baldelli
Francesca D’Angelo
Viola Pavoncello
Ersilia Vita Fiscarelli
Paolo Visca
Giordano Rampioni
Livia Leoni
Identification of FDA-approved antivirulence drugs targeting the Pseudomonas aeruginosa quorum sensing effector protein PqsE
description The ability of the bacterial pathogen Pseudomonas aeruginosa to cause both chronic and acute infections mainly relies on its capacity to finely modulate the expression of virulence factors through a complex network of regulatory circuits, including the pqs quorum sensing (QS) system. While in most QS systems the signal molecule/receptor complexes act as global regulators that modulate the expression of QS-controlled genes, the main effector protein of the pqs system is PqsE. This protein is involved in the synthesis of the QS signal molecules 2-alkyl-4(1H)-quinolones (AQs), but it also modulates the expression of genes involved in virulence factors production and biofilm formation via AQ-independent pathway(s). P. aeruginosa pqsE mutants disclose attenuated virulence in plant and animal infection models, hence PqsE is considered a good target for the development of antivirulence drugs against P. aeruginosa. In this study, the negative regulation exerted by PqsE on its own transcription has been exploited to develop a screening system for the identification of PqsE inhibitors in a library of FDA-approved drugs. This led to the identification of nitrofurazone and erythromycin estolate, two antibiotic compounds that reduce the expression of PqsE-dependent virulence traits and biofilm formation in the model strain P. aeruginosa PAO1 at concentrations far below those affecting the bacterial growth rate. Notably, both drugs reduce the production of the PqsE-controlled virulence factor pyocyanin also in P. aeruginosa strains isolated from cystic fibrosis patients, and do not antagonize the activity of antibiotics commonly used to treat P. aeruginosa infection.
format article
author Valerio Baldelli
Francesca D’Angelo
Viola Pavoncello
Ersilia Vita Fiscarelli
Paolo Visca
Giordano Rampioni
Livia Leoni
author_facet Valerio Baldelli
Francesca D’Angelo
Viola Pavoncello
Ersilia Vita Fiscarelli
Paolo Visca
Giordano Rampioni
Livia Leoni
author_sort Valerio Baldelli
title Identification of FDA-approved antivirulence drugs targeting the Pseudomonas aeruginosa quorum sensing effector protein PqsE
title_short Identification of FDA-approved antivirulence drugs targeting the Pseudomonas aeruginosa quorum sensing effector protein PqsE
title_full Identification of FDA-approved antivirulence drugs targeting the Pseudomonas aeruginosa quorum sensing effector protein PqsE
title_fullStr Identification of FDA-approved antivirulence drugs targeting the Pseudomonas aeruginosa quorum sensing effector protein PqsE
title_full_unstemmed Identification of FDA-approved antivirulence drugs targeting the Pseudomonas aeruginosa quorum sensing effector protein PqsE
title_sort identification of fda-approved antivirulence drugs targeting the pseudomonas aeruginosa quorum sensing effector protein pqse
publisher Taylor & Francis Group
publishDate 2020
url https://doaj.org/article/7e2d2cbeaef94dbdacc17226a46ffa91
work_keys_str_mv AT valeriobaldelli identificationoffdaapprovedantivirulencedrugstargetingthepseudomonasaeruginosaquorumsensingeffectorproteinpqse
AT francescadangelo identificationoffdaapprovedantivirulencedrugstargetingthepseudomonasaeruginosaquorumsensingeffectorproteinpqse
AT violapavoncello identificationoffdaapprovedantivirulencedrugstargetingthepseudomonasaeruginosaquorumsensingeffectorproteinpqse
AT ersiliavitafiscarelli identificationoffdaapprovedantivirulencedrugstargetingthepseudomonasaeruginosaquorumsensingeffectorproteinpqse
AT paolovisca identificationoffdaapprovedantivirulencedrugstargetingthepseudomonasaeruginosaquorumsensingeffectorproteinpqse
AT giordanorampioni identificationoffdaapprovedantivirulencedrugstargetingthepseudomonasaeruginosaquorumsensingeffectorproteinpqse
AT livialeoni identificationoffdaapprovedantivirulencedrugstargetingthepseudomonasaeruginosaquorumsensingeffectorproteinpqse
_version_ 1718425492112015360